Vertex Pharmaceuticals (NASDAQ:VRTX) Stock Unloaded Rep. David Taylor

Representative David Taylor (Republican-Ohio) recently sold shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX). In a filing disclosed on September 05th, the Representative disclosed that they had sold between $1,001 and $15,000 in Vertex Pharmaceuticals stock on August 26th. The trade occurred in the Representative’s “DAVID TAYLOR TRUST > SCHWAB JOINT BROKERAGE #1 (HOME GROWN)” account.

Representative David Taylor also recently made the following trade(s):

• Sold $1,001 – $15,000 in shares of Amgen (NASDAQ:AMGN) on 8/26/2026.
• Sold $1,001 – $15,000 in shares of Microsoft (NASDAQ:MSFT) on 8/26/2026.
• Purchased $1,001 – $15,000 in shares of Fifth Third Bancorp (NASDAQ:FITB) on 8/26/2026.
• Purchased $1,001 – $15,000 in shares of Broadcom (NASDAQ:AVGO) on 8/26/2026.
• Purchased $1,001 – $15,000 in shares of American Electric Power (NASDAQ:AEP) on 8/26/2026.
• Purchased $1,001 – $15,000 in shares of Installed Building Products (NYSE:IBP) on 8/14/2026.
• Sold $15,001 – $50,000 in shares of Microsoft (NASDAQ:MSFT) on 8/11/2026.
• Purchased $1,001 – $15,000 in shares of Procter & Gamble (NYSE:PG) on 8/11/2026.
• Purchased $1,001 – $15,000 in shares of Alphabet (NASDAQ:GOOGL) on 8/11/2026.
• Purchased $1,001 – $15,000 in shares of Broadcom (NASDAQ:AVGO) on 7/24/2026.

Vertex Pharmaceuticals Stock Performance

VRTX stock opened at $546.12 on Tuesday. Vertex Pharmaceuticals Incorporated has a 1-year low of $374.17 and a 1-year high of $560.25. The business’s 50 day simple moving average is $510.43 and its 200 day simple moving average is $471.81. The firm has a market capitalization of $138.61 billion, a PE ratio of 31.79, a PEG ratio of 2.37 and a beta of 0.32.

Vertex Pharmaceuticals (NASDAQ:VRTX) last announced its quarterly earnings results on Monday, August 3rd. The pharmaceutical company reported $4.73 earnings per share (EPS) for the quarter, missing the consensus estimate of $4.74 by ($0.01). Vertex Pharmaceuticals had a net margin of 35.00% and a return on equity of 23.09%. The business had revenue of $3.33 billion for the quarter, compared to analyst estimates of $3.23 billion. During the same period in the prior year, the business earned $4.52 EPS. The company’s revenue for the quarter was up 12.5% compared to the same quarter last year. As a group, sell-side analysts predict that Vertex Pharmaceuticals Incorporated will post 16.88 EPS for the current fiscal year.

Institutional Trading of Vertex Pharmaceuticals

Institutional investors have recently bought and sold shares of the business. Bangor Savings Bank raised its position in shares of Vertex Pharmaceuticals by 0.4% in the second quarter. Bangor Savings Bank now owns 4,470 shares of the pharmaceutical company’s stock valued at $2,220,000 after buying an additional 20 shares in the last quarter. Trust Point Inc. increased its stake in Vertex Pharmaceuticals by 2.7% during the 2nd quarter. Trust Point Inc. now owns 793 shares of the pharmaceutical company’s stock worth $394,000 after acquiring an additional 21 shares during the period. Williams Jones Wealth Management LLC. increased its stake in Vertex Pharmaceuticals by 1.9% during the 4th quarter. Williams Jones Wealth Management LLC. now owns 1,155 shares of the pharmaceutical company’s stock worth $524,000 after acquiring an additional 21 shares during the period. Cannell & Spears LLC raised its holdings in Vertex Pharmaceuticals by 1.2% in the 1st quarter. Cannell & Spears LLC now owns 1,983 shares of the pharmaceutical company’s stock valued at $885,000 after acquiring an additional 23 shares in the last quarter. Finally, Glenview Trust Co lifted its position in shares of Vertex Pharmaceuticals by 0.3% during the 4th quarter. Glenview Trust Co now owns 7,005 shares of the pharmaceutical company’s stock valued at $3,176,000 after acquiring an additional 24 shares during the period. Institutional investors own 90.96% of the company’s stock.

Insider Buying and Selling

In related news, CMO Carmen Bozic sold 4,062 shares of the stock in a transaction that occurred on Monday, June 15th. The shares were sold at an average price of $450.00, for a total transaction of $1,827,900.00. Following the sale, the chief marketing officer owned 16,953 shares in the company, valued at approximately $7,628,850. This trade represents a 19.33% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Duncan McKechnie sold 1,541 shares of Vertex Pharmaceuticals stock in a transaction that occurred on Thursday, July 2nd. The shares were sold at an average price of $519.00, for a total transaction of $799,779.00. Following the completion of the transaction, the executive vice president directly owned 11,001 shares in the company, valued at $5,709,519. This trade represents a 12.29% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders have sold 8,719 shares of company stock worth $4,174,147. Company insiders own 0.20% of the company’s stock.

Analysts Set New Price Targets

A number of analysts have recently issued reports on the stock. Cantor Fitzgerald raised their target price on shares of Vertex Pharmaceuticals from $590.00 to $595.00 and gave the stock an “overweight” rating in a research note on Tuesday, August 4th. Stifel Nicolaus set a $500.00 price target on shares of Vertex Pharmaceuticals in a report on Tuesday, August 4th. Wall Street Zen downgraded shares of Vertex Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Sunday, June 28th. Royal Bank Of Canada upped their target price on Vertex Pharmaceuticals from $543.00 to $570.00 and gave the company an “outperform” rating in a research report on Tuesday, July 7th. Finally, Canaccord Genuity Group increased their target price on Vertex Pharmaceuticals from $436.00 to $442.00 and gave the stock a “hold” rating in a research note on Tuesday, August 4th. One investment analyst has rated the stock with a Strong Buy rating, twenty have issued a Buy rating and two have issued a Hold rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $569.52.

About Representative Taylor

David Taylor (Republican Party) is a member of the U.S. House, representing Ohio’s 2nd Congressional District. He assumed office on January 3, 2025. His current term ends on January 3, 2027.

Taylor (Republican Party) ran for election to the U.S. House to represent Ohio’s 2nd Congressional District. He won in the general election on November 5, 2024.

David Taylor graduated from Amelia High School. Taylor earned degrees from Miami University (Ohio) and the University of Dayton School of Law. Taylor’s career experience includes working as an attorney and as a businessman at Sardinia Ready Mix, Inc.

About Vertex Pharmaceuticals

Vertex Pharmaceuticals Inc is a Boston-based biotechnology company focused on the discovery, development and commercialization of therapies for serious diseases. Founded in 1989, Vertex built its reputation on research-driven drug development and is best known for its work in cystic fibrosis (CF), where its portfolio of small-molecule CFTR modulators transformed standards of care for many people with the disease. The company operates research and development, manufacturing and commercial organizations and serves patients and healthcare systems in multiple international markets.

Vertex’s marketed products center on CFTR modulators that target the underlying cause of cystic fibrosis rather than just treating symptoms.